KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
› The briefing includes analysis of KOL opinion on the following topic areas:
– Baricitinib safety profile with regards to cardiovascular signal
– Tofacitinib safety profile with regards to cardiovascular signal
– Upadacitinib safety profile with regards to cardiovascular signal
– Filgotinib safety profile with regards to cardiovascular signal
– Most favorable JAK inhibitor with regards to cardiovascular safety
– Extent in which thromboembolic events is a class effect across all JAK inhibitors
– Additional studies / actions required to mitigate concerns around cardiovascular safety in the JAK inhibitors class
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– Five Europe-based & five US-based
– Interviews conducted in December 2017
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Majority of KOLs acknowledged that there was a CV signal with baricitinib in RA, although many flagged this was not necessarily a concern
While KOLs generally had a positive opinion of tofacitinib’s CV risk profile, many stated the need for more safety data
Most KOLs highlighted the need for additional data before drawing conclusions regarding upadacitinib’s CV safety profile
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on " Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis "
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Pfizer
AbbVie
Gilead
Galapagos
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.